Photopheresis Products Market Size, Share, Trends, Growth, Consumption, Revenue, Company Analysis and Forecast 2021-2027

Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Photopheresis Market

4. Market Overview

4.1. Introduction

4.1.1. By Product Definition

4.1.2. Industry Evolution / Developments

4.2.  Overview

4.3. Key Market Indicators

4.3.1. Region/Country Specific

4.3.2. Product/Application/Therapeutic Area Specific

4.3.3. Target Market Specific – Global Scenario

4.4. Market Dynamics

4.4.1. Drivers

4.4.2. Restraints

4.4.3. Opportunity

4.4.Global Photopheresis Products Market Forecast, 2018-2027

4.4.1.Market Size Forecast

4.4.2.Pipeline Analysis

4.5.Organ and Stem Cell Transplantations Overview

4.6.Photopheresis Therapy Snapshot

4.7. Global Photopheresis Market Analysis and Forecasts, 2018-2027

4.7.1. Market Revenue Projections (US$ Mn)

4.8. Photopheresis Market - Global Supply Demand Scenario

4.9. Porter’s Five Force Analysis

4.10. Market Outlook

5. Global Photopheresis Market Analysis and Forecasts, By Product

5.1. Introduction & Definition

5.2. Key Findings / Developments

5.3. Key Trends

5.4. Market value  Forecast By Product, 2018-2027

5.4.1. Open ECP system

5.4.2. Closed ECP system

5.5. By Product Comparison Matrix

5.6. Market Attractiveness By Product

6. Global Photopheresis Market Analysis and Forecasts, By End User

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Key Trends

6.4. Market value  Forecast By End User, 2018-2027

6.4.1. Hospitals

6.4.2. Specialty Clinics

6.5. End User  Comparison Matrix

6.6. Market Attractiveness By End User

7. Global Photopheresis Market Analysis and Forecasts, By Therapeutic Area

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Key Trends

7.4. Market value  Forecast By Therapeutic Area, 2018-2027

7.4.1. Cutaneous T-cell Lymphoma

7.4.2. Graft-versus-Host Disease

7.4.3. Transplantation rejection

7.4.4. Autoimmune Disease

7.5. Therapeutic Area  Comparison Matrix

7.6. Market Attractiveness By Therapeutic Area

8. Global Photopheresis Market Analysis and Forecasts, By Region

8.1. Key Findings

8.2. Policies and Regulations

8.3. Market value  Forecast By Region

8.3.1. North America

8.3.2. Latin America

8.3.3. APAC

8.3.4. Europe

8.3.5. MEA

8.4. Market Attractiveness By Country/Region

9. North America Photopheresis Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.1.2. Policies and Regulations

9.1.3. Price Trend Analysis

9.1.4. Key Trends

9.2. Market value  Forecast By Product, 2018-2027

9.2.1. Open ECP system

9.2.2. Closed ECP system

9.3. Market value  Forecast By End User, 2018-2027

9.3.1. Hospitals

9.3.2. Specialty Clinics

9.4. Market value  Forecast By Therapeutic Area, 2018-2027

9.4.1. Cutaneous T-cell Lymphoma

9.4.2. Graft-versus-Host Disease

9.4.3. Transplantation rejection

9.4.4. Autoimmune Disease

9.5. Market value  Forecast By Country, 2018-2027

9.5.1. US

9.5.2. Canada

9.6. Market Attractiveness Analysis

9.6.1. By Product

9.6.2. By End User

9.6.3. By Therapeutic Area

9.6.4. By Country

10. Latin America Photopheresis Market Analysis and Forecast

10.1.Introduction

10.1.1. Key Findings

10.1.2. Policies and Regulations

10.1.3. Price Trend Analysis

10.1.4. Key Trends

10.2.Market value  Forecast By Product, 2018-2027

10.2.1. Open ECP system

10.2.2. Closed ECP system

10.3.Market value  Forecast By End User, 2018-2027

10.3.1. Hospitals

10.3.2. Specialty Clinics

10.4.Market value  Forecast By Therapeutic Area, 2018-2027

10.4.1. Cutaneous T-cell Lymphoma

10.4.2. Graft-versus-Host Disease

10.4.3. Transplantation rejection

10.4.4. Autoimmune Disease

10.5.Market value  Forecast By Country, 2018-2027

10.5.1. Brazil

10.5.2. Mexico

10.5.3. Rest of Latin America

10.6.Market Attractiveness Analysis

10.6.1. By Product

10.6.2. By End User

10.6.3. By Therapeutic Area

10.6.4. By Country

11. APAC Photopheresis Market Analysis and Forecast

11.1.Introduction

11.1.1. Key Findings

11.1.2. Policies and Regulations

11.1.3. Price Trend Analysis

11.1.4. Key Trends

11.2.Market value  Forecast By Product, 2018-2027

11.2.1. Open ECP system

11.2.2. Closed ECP system

11.3.Market value  Forecast By End User, 2018-2027

11.3.1. Hospitals

11.3.2. Specialty Clinics

11.4.Market value  Forecast By Therapeutic Area, 2018-2027

11.4.1. Cutaneous T-cell Lymphoma

11.4.2. Graft-versus-Host Disease

11.4.3. Transplantation rejection

11.4.4. Autoimmune Disease

11.5.Market value  Forecast By Country, 2018-2027

11.5.1. Japan

11.5.2. India

11.5.3. China

11.5.4. Rest of APAC

11.6.Market Attractiveness Analysis

11.6.1. By Product

11.6.2. By End User

11.6.3. By Therapeutic Area

11.6.4. By Country

12. Europe Photopheresis Market Analysis and Forecast

12.1.Introduction

12.1.1. Key Findings

12.1.2. Policies and Regulations

12.1.3. Price Trend Analysis

12.1.4. Key Trends

12.2.Market value  Forecast By Product, 2018-2027

12.2.1. Open ECP system

12.2.2. Closed ECP system

12.3.Market value  Forecast By End User, 2018-2027

12.3.1. Hospitals

12.3.2. Specialty Clinics

12.4.Market value  Forecast By Therapeutic Area, 2018-2027

12.4.1. Cutaneous T-cell Lymphoma

12.4.2. Graft-versus-Host Disease

12.4.3. Transplantation rejection

12.4.4. Autoimmune Disease

12.5.Market value  Forecast By Country, 2018-2027

12.5.1. UK

12.5.2. France

12.5.3. Germany

12.5.4. Spain

12.5.5. Italy

12.5.6. Russia

12.5.7. Rest of Europe

12.6.Market Attractiveness Analysis

12.6.1. By Product

12.6.2. By End User

12.6.3. By Therapeutic Area

12.6.4. By Country

13. MEA Photopheresis Market Analysis and Forecast

13.1.Introduction

13.1.1. Key Findings

13.1.2. Policies and Regulations

13.1.3. Price Trend Analysis

13.1.4. Key Trends

13.2.Market value  Forecast By Product, 2018-2027

13.2.1. Open ECP system

13.2.2. Closed ECP system

13.3.Market value  Forecast By End User, 2018-2027

13.3.1. Hospitals

13.3.2. Specialty Clinics

13.4.Market value  Forecast By Therapeutic Area, 2018-2027

13.4.1. Cutaneous T-cell Lymphoma

13.4.2. Graft-versus-Host Disease

13.4.3. Transplantation rejection

13.4.4. Autoimmune Disease

13.5.Market value  Forecast By Country, 2018-2027

13.5.1. South Africa

13.5.2. Saudi Arabia

13.5.3. UAE

13.5.4. Rest of MEA

13.6.Market Attractiveness Analysis

13.6.1. By Product

13.6.2. By End User

13.6.3. By Therapeutic Area

13.6.4. By Country

14. Competition Landscape

14.1.Market Player – Competition Matrix (By Tier and Size of companies)

14.2.Market Share Analysis By Company (2019)

14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

14.3.1. Haemonetics Corporation

        14.3.1.1.Company Overview

        14.3.1.2.Financial Overview

        14.3.1.3.Product Portfolio

        14.3.1.4.Business Strategies

        14.3.1.5.Recent Developments

14.3.2. Fresenius Kabi AG

        14.3.2.1.Company Overview

        14.3.2.2.Financial Overview

        14.3.2.3.Product Portfolio

        14.3.2.4.Business Strategies

        14.3.2.5.Recent Developments

14.3.3. Macopharma

        14.3.3.1.Company Overview

        14.3.3.2.Financial Overview

        14.3.3.3.Product Portfolio

        14.3.3.4.Business Strategies

        14.3.3.5.Recent Developments

14.3.4. Terumo Corporation

        14.3.4.1.Company Overview

        14.3.4.2.Financial Overview

        14.3.4.3.Product Portfolio

        14.3.4.4.Business Strategies

        14.3.4.5.Recent Developments

14.3.5. Med Tech Solutions GmbH

        14.3.5.1.Company Overview

        14.3.5.2.Financial Overview

        14.3.5.3.Product Portfolio

        14.3.5.4.Business Strategies

        14.3.5.5.Recent Developments

14.3.6. Mallinckrodt Pharmaceuticals

        14.3.6.1.Company Overview

        14.3.6.2.Financial Overview

        14.3.6.3.Product Portfolio

        14.3.6.4.Business Strategies

        14.3.6.5.Recent Developments